№ files_lp_4_process_1_31029
File format: docx
Character count: 7796
File size: 171 KB
Cellular pathology audit template defining criteria, reporting elements, and data collection structure used to review compliance of histopathology reports of primary cutaneous lymphoma with dataset requirements established by the Royal College of Pathologists.
Year:
Not specified
Country / Region:
United Kingdom
Field:
Dermatopathology
Topic:
Histopathological reporting of primary cutaneous lymphoma
Document type:
Audit template and data collection proforma
Issuing organization:
Royal College of Pathologists
Reference dataset:
Dataset for Histopathological Reporting of Primary Cutaneous Lymphoma (2023)
Authors of referenced dataset:
Calonje E; Alexander S
Intended users:
Pathologists and pathology departments
Purpose:
Assessment of inclusion of core data items in histopathology reports
Audit standard:
100% inclusion of required dataset items or documented explanation for variance
Data scope:
WHO lymphoma entities, morphology, SNOMED codes, disease-specific immunophenotypic and molecular markers
Methodology:
Review of histopathology reports for cases of primary cutaneous lymphoma within a defined time period
Components:
Audit template, results table, compliance assessment, data collection proforma, audit action plan
Associated classifications:
WHO lymphoma classification; SNOMED coding
Reference source:
Royal College of Pathologists cancer datasets and tissue pathways
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2022
Region / City:
N/A
Topic:
Oncology, Pathology
Document Type:
Protocol
Organization:
CAP (College of American Pathologists)
Authors:
Raja R. Seethala, MD; Wonwoo Shon, DO; Bonnie L. Balzer, MD, PhD; Umamaheswar Duvvuri, MD, PhD; Nima M. Gharavi, MD, PhD; William Lydiatt, MD
Intended Audience:
Pathologists, Clinical Laboratories, Medical Institutions
Effective Period:
From March 2023
Approval Date:
September 2022
Amendment Date:
N/A
Document Type:
Supplementary table
Database:
Ovid MEDLINE
Subject:
Cutaneous Lupus Erythematosus and plant-derived or antimalarial interventions
Content Type:
Search strategy
Medical Subject Headings (MeSH):
Lupus Erythematosus, Cutaneous; Plants; Plant Structures; Fungi; Bacteria; Herbal Medicine; Antimalarials; Artemisinins; Chloroquine; Quinidine; Quinine
Keywords Included:
botanical terms, herbal medicine, traditional Chinese medicine, Janus kinase inhibitors, antimalarial agents, specific plant genera and compounds
Search Fields:
Title and abstract (ti,ab)
Boolean Logic:
Combination of controlled vocabulary and keyword terms using AND/OR operators
Purpose:
Identification of relevant biomedical literature
Year:
2026
Institution:
School of Pharmaceutical Sciences, Sun Yat-sen University, Shenzhen Campus
Authors:
Jing Li, Hong Gao, Yue Xiong, Ling Wang, Haojie Zhang, Fumei He, Jingxin Zhao, Shuna Liu, Liqian Gao, Ying Guo, Wenbin Deng
Correspondence:
Ying Guo, Wenbin Deng
Document type:
Supplementary information
Subject area:
Regenerative medicine, wound healing, neural stem cells, exosomes
Data content:
Proteomic analysis of NSC-derived exosomes, immunofluorescence quantification of Gap43 in skin sections
Target organism:
Homo sapiens
Methodology:
Protein identification and quantification, immunofluorescence microscopy
Figures and tables:
Table S1 (top 100 abundant proteins in NSC-exo), Figure S1 (quantitative analysis of Gap43)
Keywords:
Cutaneous wound healing, NSC-exosomes, proteomics, Gap43
Year:
2022
Journal:
World Journal of Clinical Cases
Manuscript Type:
Case Report
Authors:
Miao Zhang, Jia Chen, Chun-Xiao Wang, Nai-Xuan Lin, Xin Li
Affiliations:
Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine; Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine; Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University
Corresponding Author:
Xin Li, MD, PhD
Received Date:
May 31, 2022
Revised Date:
July 9, 2022
Accepted Date:
August 23, 2022
Published Online:
2022
Keywords:
Vitamin K1, Subcutaneous injection, Adverse reactions, Herbal medicine, Polyoxyethylated castor oil, Case report guidelines
Target Audience:
Clinicians, Dermatologists, Researchers in clinical medicine
Patient Age:
50 years
Patient Condition:
Cutaneous allergic reaction to vitamin K1
Treatment:
Chinese herbal medicine, topical and intralesional steroids
Follow-up Duration:
32 months
Date:
25th March 2026
Location:
All Nations Centre, Achville Avenue Heath, Cardiff CF14 3NY
Event Type:
Hybrid Meeting
Target Audience:
Healthcare professionals interested in cutaneous allergies
Registration Deadline:
Not specified
Registration Fee:
Free of charge
Required Action:
RSVP and indicate attendance, lunch preference, and dietary needs
Language:
English
Year:
2023
Region / city:
Australia
Topic:
Oncology, Pharmaceuticals
Document Type:
Resubmission
Institution:
Australian Government, Pharmaceutical Benefits Advisory Committee
Author:
AstraZeneca Pty Ltd.
Target Audience:
Healthcare professionals, regulatory bodies
Effective Period:
Ongoing
Approval Date:
November 2021
Date of Changes:
November 2021
Author:
Dr. Mark Bishton, Honorary Consultant Haematologist, Nottingham University [email protected]
Version:
Draftv1.2
Ratified by & Date:
EM Haematology ECAG 03/10/2025
Review date:
October 2027
Explicit definition of patient group to which it applies:
Patients with Lymphoma receiving steroid containing chemotherapy regimens
NICE guidance reference:
N/A
Note:
Summary of evidence base this guideline has been created from
Version No.:
1.0, 1.1, 1.2
Date:
March 2025, July, September
Revision Author:
M Bishton
Status:
Draft, FINAL
Description:
Updates on bisphosphonate use and recent ECAG review
Indication of prophylaxis:
Bisphosphonate prophylaxis for patients with at least 1 listed risk factor
Bisphosphonate agents:
Alendronic acid, Zolendronic acid, Risedronate, Denosumab
Adjunctive treatment:
Vitamin D supplementation required
Authors:
Luminari S; Donati B; Casali M; Valli R; Santi R; Puccini B; Kovalchuk S; Ruffini A; Fama A; Berti V; Fragliasso V; Zanelli M; Vergoni F; Versari A; Rigacci L; Merli F; Ciarrocchi A
Affiliations:
Hematology Unit, AUSL-IRCCS, Reggio Emilia; University of Modena and Reggio Emilia; Laboratory of Translational Research, AUSL-IRCCS, Reggio Emilia; Nuclear Medicine, AUSL-IRCCS, Reggio Emilia; Pathology Unit, AUSL IRCCS, Reggio Emilia; Pathology Unit, Careggi University Hospital, Firenze; Hematology, AOSP Careggi, Firenze; Gruppo Amici Dell’Ematologia Foundation (GrADE); Nuclear Medicine, University of Firenze; Hematology and Stem Cell Transplant AO San Camillo Forlanini, Roma
Corresponding authors:
Alessia Ciarrocchi; Stefano Luminari
Country:
Italy
Institutions:
AUSL-IRCCS Reggio Emilia; University of Modena and Reggio Emilia; Careggi University Hospital Firenze; University of Firenze; AO San Camillo Forlanini Roma
Medical field:
Hematology; Oncology; Molecular diagnostics
Disease:
Classical Hodgkin Lymphoma
Treatment regimen:
ABVD
Study population:
Previously untreated stage I–IV classical Hodgkin Lymphoma patients
Sample size:
238 patients (121 training set; 117 validation set)
Methodology:
Digital gene expression profiling (NanoString Technology); multivariate regression analysis; five-point Deauville scale assessment
Genes analyzed:
770 immune-related genes
Primary endpoint:
Prediction of interim FDG-PET positivity after two cycles of ABVD
Running title:
Gene predictive model for interim PET in Hodgkin Lymphoma
Keywords:
Hodgkin Lymphoma; metabolic response; interim PET; gene-based predictive model; tumor microenvironment
Word count:
4124
Year:
2017
Region / City:
Texas
Subject:
Healthcare, Cancer Treatment
Document Type:
Report
Organization / Institution:
MD Anderson Cancer Center
Author:
Not specified
Target Audience:
Healthcare professionals, administrators
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
Not specified
Region / City:
Not specified
Theme:
Oncology, Hematology
Document Type:
Scientific Research
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, researchers
Action Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2017
Country:
Australia
Program:
Pharmaceutical Benefits Scheme (PBS)
Section:
Section 100 Highly Specialised Drugs Program
Regulatory Authority:
Pharmaceutical Benefits Advisory Committee (PBAC)
Regulatory Agency:
Department of Human Services
Drug Name:
Pralatrexate
Brand Name:
Folotyn®
Manufacturer:
Mundipharma Pty Ltd
Dosage Form:
Solution for intravenous infusion, 20 mg in 1 mL
Maximum Quantity:
80 mg
Indication:
Relapsed or chemotherapy-refractory peripheral T-cell lymphoma
Target Population:
Adult patients with relapsed or refractory peripheral T-cell lymphoma after first-line chemotherapy
Treatment Regimen:
30 mg/m² intravenous infusion weekly for six weeks followed by one week rest
Treatment Phases:
Initial treatment; continuing treatment
Restriction Type:
Authority Required (Private and Public Hospital)
Clinical Criteria:
Relapsed or chemotherapy-refractory disease following front-line curative intent chemotherapy
Comparator Treatments:
DHAP, brentuximab, gemcitabine-containing regimens, methotrexate, romidepsin, ESHAP, ICE
Outcome Measures:
Overall survival, overall response rate, safety
Regulatory Status:
Registered by the Therapeutic Goods Administration (TGA) in December 2014
Therapeutic Area:
Oncology / Hematologic malignancies
Year:
2021
Region / City:
Omaha, NE
Theme:
Hematopoietic Cellular Therapy
Document Type:
Standard Operating Procedure
Organization / Institution:
FACT Accreditation
Author:
FACT
Target Audience:
Medical Facilities, Accreditation Inspectors
Period of Validity:
N/A
Date of Approval:
December 14, 2021
Date of Changes:
N/A
Year:
2023-2024
Region / City:
Las Vegas, NV
Subject:
Biological Sciences - Cellular and Molecular Biology
Document Type:
Educational Catalog
Institution:
University of Nevada, Las Vegas
Target Audience:
Graduate Students
Period of Action:
2023-2024
Approval Date:
N/A
Modification Date:
N/A
Note:
Year
Region / City:
United States
Topic:
Pharmaceutical naming and regulatory processes
Document type:
Application form
Organization / Institution:
United States Adopted Names Council, American Medical Association
Target audience:
Pharmaceutical companies, researchers, regulatory authorities
Year:
2023
Region / City:
Not specified
Subject:
Biology
Document Type:
Laboratory experiment
Institution:
Not specified
Author:
Not specified
Target Audience:
Students
Period of Effect:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / City:
Guelph
Topic:
Microscopy Services
Document Type:
Service Description
Institution:
University of Guelph
Author:
Dr. Michaela Strueder-Kypke
Target Audience:
Researchers, Lab Technicians, Students
Period of Validity:
May 2023 - April 2024
Approval Date:
Not specified
Modification Date:
Not specified
Contact Information:
[email protected]
Website:
https://www.uoguelph.ca/aac/mcif
Year:
2023
Region / City:
United States
Topic:
Hematopoietic Cell Transplantation, Cellular Therapies, Research Databases
Document Type:
Consent Form
Organization / Institution:
CIBMTR (Center for International Blood and Marrow Transplant Research)
Author:
CIBMTR
Target Audience:
Patients and/or parents/legal guardians of recipients of hematopoietic cell transplants or cellular therapies
Effective Period:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Year:
2019
Region / City:
N/A
Topic:
Pubertal Timing, Cellular Aging, Adversities
Document Type:
Research Supplement
Institution:
N/A
Author:
Multiple authors including Amir et al., Boynton-Jarrett & Harville, Mendle et al.
Target Audience:
Researchers, Academics in the field of Pubertal Development and Aging
Period of validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Contextual Description:
A research supplement containing detailed effect sizes and corresponding sampling variances for studies in a meta-analysis on the relationship between adversity and pubertal timing, as well as cellular aging.